Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pacira Pharm Inc
(NQ:
PCRX
)
14.54
+0.21 (+1.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pacira Pharm Inc
< Previous
1
2
3
4
5
6
Next >
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Despite its impressive fundamentals, NASDAQ:PCRX remains undervalued.
March 28, 2024
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
March 20, 2024
Via
AB Newswire
Topics
Death
Exposures
Death
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
March 13, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Navigating 4 Analyst Ratings For Pacira BioSciences
March 01, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Preview: Pacira BioSciences's Earnings
February 28, 2024
Via
Benzinga
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
March 06, 2024
From
Pacira BioSciences
Via
GlobeNewswire
When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
March 01, 2024
Don't overlook PACIRA BIOSCIENCES INC (NASDAQ:PCRX)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
February 29, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
February 22, 2024
From
Pacira BioSciences
Via
GlobeNewswire
NASDAQ:PCRX is an undervalued gem with solid fundamentals.
January 19, 2024
PACIRA BIOSCIENCES INC (NASDAQ:PCRX), an undervalued stock with good fundamentals.
Via
Chartmill
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts
December 20, 2023
Via
Benzinga
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
February 15, 2024
From
Pacira BioSciences
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
February 12, 2024
Via
Benzinga
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
February 09, 2024
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
February 07, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Earnings Preview: Pacira BioSciences
November 01, 2023
Via
Benzinga
Analyst Expectations for Pacira BioSciences's Future
October 23, 2023
Via
Benzinga
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
January 04, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira Appoints Frank D. Lee as Chief Executive Officer
December 21, 2023
From
Pacira BioSciences
Via
GlobeNewswire
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
December 20, 2023
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals.
Via
Chartmill
Investors should take notice of NASDAQ:PCRX—it offers a great deal for the fundamentals it presents.
November 29, 2023
Despite its impressive fundamentals, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) remains undervalued.
Via
Chartmill
Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications
November 10, 2023
From
Pacira BioSciences
Via
GlobeNewswire
For those who appreciate value investing, NASDAQ:PCRX is a compelling option with its solid fundamentals.
November 08, 2023
Investors should take notice ofPACIRA BIOSCIENCES INC (NASDAQ:PCRX)—it offers a great deal for the fundamentals it presents.
Via
Chartmill
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November
November 07, 2023
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Third Quarter 2023 Financial Results
November 02, 2023
From
Pacira BioSciences
Via
GlobeNewswire
Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023
October 26, 2023
From
Pacira BioSciences
Via
GlobeNewswire
American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.
October 12, 2023
From
Pacira BioSciences
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.